Brighton Jones’s Aldeyra Therapeutics ALDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-16,144
Closed -$34.4K – 1390
2026
Q2
$34.4K Sell
16,144
-6,055
-27% -$10.4K ﹤0.01% 1383
2026
Q1
$37.5K Buy
+22,199
New +$97.3K ﹤0.01% 1174
2025
Q4
– Sell
-19,945
Closed -$104K – 86
2025
Q3
$104K Buy
19,945
+2,046
+11% +$10.7K ﹤0.01% 990
2025
Q2
$68.6K Buy
+17,899
New +$46.3K ﹤0.01% 901

Other funds holding ALDX

Brighton Jones's ALDX Position: Q3 2026 in Review

Brighton Jones sold out of Aldeyra Therapeutics (ALDX) in Q3 2026, closing a stake of 16,144 shares — an estimated $34.4K sold.

Brighton Jones first reported a position in ALDX in Q2 2025 and held it in 4 quarters. The position peaked at $104K in Q3 2025. 71 funds tracked by Wall St. Rank hold ALDX as of Q3 2026.

  • Brighton Jones reported no remaining Aldeyra Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Brighton Jones sold 16,144 Aldeyra Therapeutics shares in Q3 2026, an estimated $34.4K.
  • Brighton Jones first reported a position in Aldeyra Therapeutics in Q2 2025 and held it in 4 quarters.
  • Brighton Jones's Aldeyra Therapeutics position peaked at $104K in Q3 2025.
  • 71 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.